Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?

Millennium Management more than doubled its AbbVie position to 1.5 million shares, valued at roughly $380 million, implying about $10.3 million in annual dividends at AbbVie's 2.7% yield. AbbVie's Skyrizi and Rinvoq generated $9.99 billion and $4.64 billion, respectively, in first-half 2026 sales, while its dividend has compounded at a 5.9% annual rate over five years. The investment case is tempered by a 7.2x price-to-sales valuation and acquisition-related spending, including an $11 billion purchase of Apogee Therapeutics.

Analysis

The incremental signal from a multi-manager ownership change is weak: Millennium runs a large, frequently rebalanced book, so the position does not establish a fundamental catalyst or a directional conviction signal without knowing its options overlay, sector hedge, and purchase cost. More importantly, the reported Apogee transaction appears inconsistent with publicly verifiable corporate history; that data-integrity issue makes any leverage or M&A conclusion from the article unusable. ABBV should be underwritten instead on post-Humira erosion stabilization, immunology franchise durability, and acquired-product integration rather than on reported fund activity.

Near term, ABBV's principal risk is valuation de-rating if Skyrizi/Rinvoq growth decelerates before the market has confidence that newer indications and aesthetics can offset legacy-product pressure. Over 6-18 months, successful immunology execution can support premium multiples versus large-cap pharma, but a higher-for-longer rate backdrop limits the value of the dividend-growth narrative because the equity competes directly with risk-free income. The non-obvious competitive read-through is negative for APGE only if ABBV's internal/partnered immunology pipeline reduces demand for external late-stage atopic-dermatitis assets; there is no actionable evidence here that such a transaction is occurring.

Contrarian view: the market may be too focused on headline revenue replacement and insufficiently focused on concentration risk. A substantial portion of incremental growth depends on two immunology brands, making payer pushback, biosimilar-adjacent pricing pressure, or safety-label changes more consequential to the multiple than the current diversified-business framing implies. This is a quality compounder watch item, not a catalyst-driven long from this article alone.

Key Decisions for Investors

• No new ABBV position solely on this report; require verification of M&A claims and the next earnings update on Skyrizi/Rinvoq volume, net-price, and full-year guidance before upgrading conviction.
• For an existing ABBV long, retain only if management reaffirms immunology growth sufficient to cover legacy-product declines and maintains leverage/deleveraging targets; trim on a guidance reduction or material deterioration in net pricing.
• Watch ABBV versus the XLV ETF over the next 1-3 months: relative outperformance following validated immunology guidance would support a quality-pharma long, while relative weakness despite stable sector conditions would indicate multiple compression is dominating fundamentals.
• Monitor APGE as an M&A-alert name rather than a recommendation. A verified strategic approach, partnership, or clinical-data catalyst could alter competitive value; absent that evidence, the article provides no basis to price an acquisition premium.